Positive opinion for all 3 Orphan applications in Europe
Filed with ASX · · 2 pages · English
Neuren Pharmaceuticals Limited on 6ix
Story so far
Earlier from Neuren Pharmaceuticals
- Approval received for final stage of NNZ-2591 clinical trial
- Quarterly report and cash flow statement for Q3 2020
- Neuren initiates manufacture of NNZ-2591 for Phase 2 trials
- Q2 2020 Activity Report and Cash Flow Report
- Proposed issue of Securities - NEU
Later from Neuren Pharmaceuticals
- European Commission grants 3 NNZ-2591 Orphan designations
- Quarterly report and cash flow statement for Q4 2020
- Successful Phase 1 trial for Neurens NNZ-2591
- Neuren adds Prader-Willi syndrome to NNZ-2591 pipeline
- Preliminary Final Report and 2020 full year accounts
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals